



PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3**Complete if Known**

Application Number	10/541,664
Filing Date	July 7, 2005
First Named Inventor	William Brown
Art Unit	Unknown 1625
Examiner Name	Unknown 60149701
Attorney Docket Number	100953-1P US

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
<i>K</i>		US- 2,898,339	08/04/1959	Wheeler et al.	
<i>K</i>		US- 4,581,171	04/08/1986	Kennis et al.	
<i>K</i>		US- 4,816,586	03/28/1989	Portoghese	
<i>K</i>		US- 4,939,137	07/03/1990	Russell et al.	
<i>K</i>		US- 5,140,029	08/18/1992	Kennis et al.	
<i>K</i>		US- 5,574,159	11/12/1996	Chang et al.	
<i>K</i>		US- 5,683,998	11/04/1997	Shibayama et al.	
<i>K</i>		US- 6,187,792	02/13/2001	Delorme et al.	
<i>K</i>		US- 6,455,545	09/24/2002	Delorme et al.	
<i>K</i>		US- 6,552,036	04/22/2003	Boyd et al.	
<i>K</i>		US- 6,556,387	04/29/2003	Misso et al.	
<i>K</i>		US- 6,756,387	06/29/2004	Brown et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁴
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
<i>K</i>		WO 93/15062	08/05/1993	The Wellcome Foundation		
<i>K</i>		WO 97/23466	07/03/1997	Astra Aktiebolag		
<i>K</i>		WO 98/28275	07/02/1998	Astra Pharma, Inc.		
<i>K</i>		WO 99/33806	07/08/1999	Ortho-McNeil Pharmaceutical		
<i>K</i>		WO 01/74804	10/11/2001	AstraZeneca AB		
<i>K</i>		WO 01/74806	10/11/2001	AstraZeneca AB		

Examiner
Signature*Raymond Costa*Date
Considered

5/24/08

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Sheet	2	of	3
-------	---	----	---

Application Number	10/541,664
Filing Date	July 7, 2005
First Named Inventor	William Brown
Art Unit	Unknown 1625
Examiner Name	Unknown 6044976
Attorney Docket Number	100953-1P US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
7/10		WO 02/094786	11/28/2002	AstraZeneca AB		
		WO 02/094812	11/28/2002	AstraZeneca AB		

**Examiner
Signature**

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/541,664
		Filing Date	July 7, 2005
		First Named Inventor	William Brown
		Art Unit	Unknown 1625
		Examiner Name	Unknown Corrigan
Sheet 3	of 3	Attorney Docket Number	100953-1P US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
R		BARBER, A. et al., "Antinociceptive effects of the 5-HT ₂ Antagonist Ritanserin in Rats: Evidence... in the Spinal Cord," Neuroscience Letters, 1989, Vol. 99, p. 234-238	
R		BILSKY, E. et al., "SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist," J. Pharmacology Experimental Ther., 1995, Vol. 273, p. 359-366	
R		GREENE, T., "Protective Groups in Organic Synthesis," Wiley & Sons, 1982, p. 218, 220, 232, 233, 251	
R		TAKEMORI, A.E. et al., "Selective Naltrexone-Derived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol., 1992, Vol. 32, p. 239-269	
R		WEI, Z. et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: A Novel...and its Analogues," J. Med. Chem., 2000, Vol. 43, p. 3895-3905	
R		ZHANG, X. et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis... Opioid Receptor Ligands, J. Med. Chem., 1999, Vol. 42, p. 5455-5463	

Examiner Signature	<i>Raymond Corrigan</i>	Date Considered	5/24/08
--------------------	-------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.